4DMT Reports FY25 Results, Highlights Progress Across Retinal And Pulmonary Pipeline

4D Molecular Therapeutics reported full-year 2025 results, highlighting strong operational progress and a narrowed net loss versus the prior year. The update signals improving financial trajectory and execution for the biotech, which could support near-term stock upside, though the release lacked detailed revenue, EPS or forward guidance.

Analysis

4D Molecular Therapeutics reported full-year 2025 results, highlighting strong operational progress and a narrowed net loss versus the prior year. The update signals improving financial trajectory and execution for the biotech, which could support near-term stock upside, though the release lacked detailed revenue, EPS or forward guidance.